Effects of sodium–glucose cotransporter 2 inhibitors in addition to insulin therapy on cardiovascular risk factors in type 2 diabetes patients: A meta‐analysis of randomized controlled trials
Abstract Aims/Introduction In the present meta‐analysis, we aimed to determine the effects of sodium–glucose cotransporter 2 inhibitor (SGLT‐2i) in addition to insulin therapy on cardiovascular risk factors in type 2 diabetes patients. Materials and Methods Randomized controlled trials were identifi...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-03-01
|
Series: | Journal of Diabetes Investigation |
Subjects: | |
Online Access: | https://doi.org/10.1111/jdi.12876 |
id |
doaj-30830de787bb49c3aea435463ad523ea |
---|---|
record_format |
Article |
spelling |
doaj-30830de787bb49c3aea435463ad523ea2021-05-02T03:16:11ZengWileyJournal of Diabetes Investigation2040-11162040-11242019-03-0110244645710.1111/jdi.12876Effects of sodium–glucose cotransporter 2 inhibitors in addition to insulin therapy on cardiovascular risk factors in type 2 diabetes patients: A meta‐analysis of randomized controlled trialsBingshu Wu0Hongzhi Zheng1Jianqiu Gu2Yan Guo3Yixuan Liu4Yingfang Wang5Feng Chen6Aolin Yang7Jiabei Wang8Hailong Wang9Ying Liu10Difei Wang11Department of Geriatric Endocrinology The First Affiliated Hospital of China Medical University Shenyang Liaoning ChinaDepartment of Geriatric Endocrinology The First Affiliated Hospital of China Medical University Shenyang Liaoning ChinaDepartment of EndocrinologyThe First Affiliated Hospital of China Medical University Shenyang Liaoning ChinaDepartment of Geriatric Endocrinology The First Affiliated Hospital of China Medical University Shenyang Liaoning ChinaDepartment of Geriatric Endocrinology The First Affiliated Hospital of China Medical University Shenyang Liaoning ChinaDepartment of Geriatric Endocrinology The First Affiliated Hospital of China Medical University Shenyang Liaoning ChinaDepartment of Geriatric Endocrinology The First Affiliated Hospital of China Medical University Shenyang Liaoning ChinaDepartment of Geriatric Endocrinology The First Affiliated Hospital of China Medical University Shenyang Liaoning ChinaDepartment of Geriatric Endocrinology The First Affiliated Hospital of China Medical University Shenyang Liaoning ChinaDepartment of Epidemiology and Evidence‐based Medicine The First Affiliated Hospital of China Medical University Shenyang Liaoning ChinaDepartment of Biochemistry and Molecular Biology China Medical University Shenyang Liaoning ChinaDepartment of Geriatric Endocrinology The First Affiliated Hospital of China Medical University Shenyang Liaoning ChinaAbstract Aims/Introduction In the present meta‐analysis, we aimed to determine the effects of sodium–glucose cotransporter 2 inhibitor (SGLT‐2i) in addition to insulin therapy on cardiovascular risk factors in type 2 diabetes patients. Materials and Methods Randomized controlled trials were identified by searching the PubMed, Embase and Cochrane Library databases published before September 2017. The intervention group received SGLT‐2i as add‐on treatment to insulin therapy, and the control group received placebos in addition to insulin. We assessed pooled data, including weighted mean differences and 95% confidence intervals (CIs) using a random‐effects model. Results A total of 10 randomized controlled trials (n = 5,159) were eligible. The weighted mean differences for systolic blood pressure and diastolic blood pressure were −3.17 mmHg (95% CI −4.53, −1.80, I2 = 0%) and −1.60 mmHg (95% CI −2.52, −0.69, I2 = 0%) in the intervention groups. Glycosylated hemoglobin, fasting plasma glucose, postprandial glucose and daily insulin were also lower in the intervention groups, with relative weighted mean differences of −0.49% (95% CI −0.71, −0.28%, I2 = 92%), −1.10 mmol/L (95% CI −1.69, −0.51 mmol/L, I2 = 84%), −3.63 mmol/L (95% CI −4.36, −2.89, I2 = 0%) and −5.42 IU/day (95% CI −8.12, −2.72, I2 = 93%). The transformations of uric acid and bodyweight were −26.16 μmol/L (95% CI −42.14, −10.17, I2 = 80%) and −2.13 kg (95% CI −2.66, −1.60, I2 = 83%). The relative risk of hypoglycemia was 1.09 (95% CI 1.02, 1.17, P < 0.01). The relative risks of urinary tract and genital infection were 1.29 (95% CI 1.03, 1.62, P = 0.03) and 5.25 (95% CI 3.55, 7.74, P < 0.01). Conclusions The results showed that in the intervention group, greater reductions were achieved for blood pressure, glucose control, uric acid and bodyweight. This treatment regimen might therefore provide beneficial effects on the occurrence and development of cardiovascular events.https://doi.org/10.1111/jdi.12876Cardiovascular risk factorsMeta‐analysisSodium–glucose cotransporter 2 inhibitor |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Bingshu Wu Hongzhi Zheng Jianqiu Gu Yan Guo Yixuan Liu Yingfang Wang Feng Chen Aolin Yang Jiabei Wang Hailong Wang Ying Liu Difei Wang |
spellingShingle |
Bingshu Wu Hongzhi Zheng Jianqiu Gu Yan Guo Yixuan Liu Yingfang Wang Feng Chen Aolin Yang Jiabei Wang Hailong Wang Ying Liu Difei Wang Effects of sodium–glucose cotransporter 2 inhibitors in addition to insulin therapy on cardiovascular risk factors in type 2 diabetes patients: A meta‐analysis of randomized controlled trials Journal of Diabetes Investigation Cardiovascular risk factors Meta‐analysis Sodium–glucose cotransporter 2 inhibitor |
author_facet |
Bingshu Wu Hongzhi Zheng Jianqiu Gu Yan Guo Yixuan Liu Yingfang Wang Feng Chen Aolin Yang Jiabei Wang Hailong Wang Ying Liu Difei Wang |
author_sort |
Bingshu Wu |
title |
Effects of sodium–glucose cotransporter 2 inhibitors in addition to insulin therapy on cardiovascular risk factors in type 2 diabetes patients: A meta‐analysis of randomized controlled trials |
title_short |
Effects of sodium–glucose cotransporter 2 inhibitors in addition to insulin therapy on cardiovascular risk factors in type 2 diabetes patients: A meta‐analysis of randomized controlled trials |
title_full |
Effects of sodium–glucose cotransporter 2 inhibitors in addition to insulin therapy on cardiovascular risk factors in type 2 diabetes patients: A meta‐analysis of randomized controlled trials |
title_fullStr |
Effects of sodium–glucose cotransporter 2 inhibitors in addition to insulin therapy on cardiovascular risk factors in type 2 diabetes patients: A meta‐analysis of randomized controlled trials |
title_full_unstemmed |
Effects of sodium–glucose cotransporter 2 inhibitors in addition to insulin therapy on cardiovascular risk factors in type 2 diabetes patients: A meta‐analysis of randomized controlled trials |
title_sort |
effects of sodium–glucose cotransporter 2 inhibitors in addition to insulin therapy on cardiovascular risk factors in type 2 diabetes patients: a meta‐analysis of randomized controlled trials |
publisher |
Wiley |
series |
Journal of Diabetes Investigation |
issn |
2040-1116 2040-1124 |
publishDate |
2019-03-01 |
description |
Abstract Aims/Introduction In the present meta‐analysis, we aimed to determine the effects of sodium–glucose cotransporter 2 inhibitor (SGLT‐2i) in addition to insulin therapy on cardiovascular risk factors in type 2 diabetes patients. Materials and Methods Randomized controlled trials were identified by searching the PubMed, Embase and Cochrane Library databases published before September 2017. The intervention group received SGLT‐2i as add‐on treatment to insulin therapy, and the control group received placebos in addition to insulin. We assessed pooled data, including weighted mean differences and 95% confidence intervals (CIs) using a random‐effects model. Results A total of 10 randomized controlled trials (n = 5,159) were eligible. The weighted mean differences for systolic blood pressure and diastolic blood pressure were −3.17 mmHg (95% CI −4.53, −1.80, I2 = 0%) and −1.60 mmHg (95% CI −2.52, −0.69, I2 = 0%) in the intervention groups. Glycosylated hemoglobin, fasting plasma glucose, postprandial glucose and daily insulin were also lower in the intervention groups, with relative weighted mean differences of −0.49% (95% CI −0.71, −0.28%, I2 = 92%), −1.10 mmol/L (95% CI −1.69, −0.51 mmol/L, I2 = 84%), −3.63 mmol/L (95% CI −4.36, −2.89, I2 = 0%) and −5.42 IU/day (95% CI −8.12, −2.72, I2 = 93%). The transformations of uric acid and bodyweight were −26.16 μmol/L (95% CI −42.14, −10.17, I2 = 80%) and −2.13 kg (95% CI −2.66, −1.60, I2 = 83%). The relative risk of hypoglycemia was 1.09 (95% CI 1.02, 1.17, P < 0.01). The relative risks of urinary tract and genital infection were 1.29 (95% CI 1.03, 1.62, P = 0.03) and 5.25 (95% CI 3.55, 7.74, P < 0.01). Conclusions The results showed that in the intervention group, greater reductions were achieved for blood pressure, glucose control, uric acid and bodyweight. This treatment regimen might therefore provide beneficial effects on the occurrence and development of cardiovascular events. |
topic |
Cardiovascular risk factors Meta‐analysis Sodium–glucose cotransporter 2 inhibitor |
url |
https://doi.org/10.1111/jdi.12876 |
work_keys_str_mv |
AT bingshuwu effectsofsodiumglucosecotransporter2inhibitorsinadditiontoinsulintherapyoncardiovascularriskfactorsintype2diabetespatientsametaanalysisofrandomizedcontrolledtrials AT hongzhizheng effectsofsodiumglucosecotransporter2inhibitorsinadditiontoinsulintherapyoncardiovascularriskfactorsintype2diabetespatientsametaanalysisofrandomizedcontrolledtrials AT jianqiugu effectsofsodiumglucosecotransporter2inhibitorsinadditiontoinsulintherapyoncardiovascularriskfactorsintype2diabetespatientsametaanalysisofrandomizedcontrolledtrials AT yanguo effectsofsodiumglucosecotransporter2inhibitorsinadditiontoinsulintherapyoncardiovascularriskfactorsintype2diabetespatientsametaanalysisofrandomizedcontrolledtrials AT yixuanliu effectsofsodiumglucosecotransporter2inhibitorsinadditiontoinsulintherapyoncardiovascularriskfactorsintype2diabetespatientsametaanalysisofrandomizedcontrolledtrials AT yingfangwang effectsofsodiumglucosecotransporter2inhibitorsinadditiontoinsulintherapyoncardiovascularriskfactorsintype2diabetespatientsametaanalysisofrandomizedcontrolledtrials AT fengchen effectsofsodiumglucosecotransporter2inhibitorsinadditiontoinsulintherapyoncardiovascularriskfactorsintype2diabetespatientsametaanalysisofrandomizedcontrolledtrials AT aolinyang effectsofsodiumglucosecotransporter2inhibitorsinadditiontoinsulintherapyoncardiovascularriskfactorsintype2diabetespatientsametaanalysisofrandomizedcontrolledtrials AT jiabeiwang effectsofsodiumglucosecotransporter2inhibitorsinadditiontoinsulintherapyoncardiovascularriskfactorsintype2diabetespatientsametaanalysisofrandomizedcontrolledtrials AT hailongwang effectsofsodiumglucosecotransporter2inhibitorsinadditiontoinsulintherapyoncardiovascularriskfactorsintype2diabetespatientsametaanalysisofrandomizedcontrolledtrials AT yingliu effectsofsodiumglucosecotransporter2inhibitorsinadditiontoinsulintherapyoncardiovascularriskfactorsintype2diabetespatientsametaanalysisofrandomizedcontrolledtrials AT difeiwang effectsofsodiumglucosecotransporter2inhibitorsinadditiontoinsulintherapyoncardiovascularriskfactorsintype2diabetespatientsametaanalysisofrandomizedcontrolledtrials |
_version_ |
1721495729447370752 |